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Down syndrome (DS) is caused by trisomy of chromosome 21 (Hsa21) and is associated with a number of
deleterious phenotypes, including learning disability, heart defects, early-onset Alzheimer’s disease and
childhood leukaemia. Individuals with DS are affected by these phenotypes to a variable extent; understand-
ing the cause of this variation is a key challenge. Here, we review recent research progress in DS, both in
patients and relevant animal models. In particular, we highlight exciting advances in therapy to improve cog-
nitive function in people with DS and the significant developments in understanding the gene content of
Hsa21. Moreover, we discuss future research directions in light of new technologies. In particular, the use
of chromosome engineering to generate new trisomic mouse models and large-scale studies of genotype–
phenotype relationships in patients are likely to significantly contribute to the future understanding of DS.
INTRODUCTION
Down syndrome (DS) is caused by trisomy of human chromo-
some 21 (Hsa21). Approximately 0.45% of human con-
ceptions are trisomic for Hsa21 (1). The incidence of
trisomy is influenced by maternal age and differs between
populations (between 1 in 319 and 1 in 1000 live births are tri-
somic for Hsa21) (2–6). Trisomic fetuses are at an elevated
risk of miscarriage, and people with DS have an increased
risk of developing several medical conditions (7). Recent
advances in medical treatment and social inclusion have sig-
nificantly increased the life expectancy of people with DS.
In economically developed countries, the average life span
of people who are trisomic for Hsa21 is now greater than 55
years (8). In this review, we will discuss novel findings in
the understanding of DS and highlight future important
avenues of research.
The additional copy of Hsa21, in people with DS, is pro-
posed to result in the increased expression of many of the
genes encoded on this chromosome. The imbalance in
expression of Hsa21 and non-Hsa21 genes is hypothesized
to result in the many phenotypes that characterize DS.
However, only some of the Hsa21 genes are likely to be
dosage-sensitive, such that the phenotype they confer is
altered by gene-copy number. Thus to understand DS, it is
crucial both to understand the genomic content of Hsa21 and
to evaluate how the expression levels of these genes are
altered by the presence of a third copy of Hsa21. There have
been a number of recent advances in genomics relevant to
DS. For example, the traditional definition of a gene has
been modified (Box 1). A number of fusion transcripts that
are encoded by two or more genes previously considered to
be separate have been reported, such as the transcript
encoded by exons from the Hsa21, DONSON and ATP50
genes (9). Whether these transcripts represent novel genes
has yet to be determined. However, the number of genes
recognized on Hsa21 is likely to continue to increase from
the current count of more than 400 (10). In particular, as
algorithms to identify non-coding RNAs (e.g. microRNAs)
improve, the number of recognized genes may increase. Five
microRNAs have been identified on Hsa21 (11,12). Micro-
RNAs regulate the expression of other genes (13), and their
role in DS is not fully understood. Spatial and temporal
mapping of the Hsa21 gene expression is also critical to the
understanding of DS. The increase in expression of some
Hsa21 genes caused by trisomy of Hsa21 has been recently
shown to lie within the range of natural variations in
the expression of these genes in the euploid population
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(14,15). Similar findings have also been reported in
the Ts(1716)65Dn (Ts65Dn) mouse model of DS (Fig. 1) (16).
Box 1:What is a gene?
The definition of a gene has shifted over the past 100 years
since it was first coined by Wilhelm Johannsen in 1909,
based on the ideas of Mendel, de Vries, Correns and
Tschermak. Their original theoretical definition of the
gene being ‘the smallest unit of genetic inheritance’
remains the cornerstone of our understanding; however,
the definition has grown with our knowledge of molecular
biology. The gene has recently been defined as ‘a union of
genomic sequences encoding a coherent set of potentially
overlapping functional products’ (133). Splicing generates
multiple transcripts from one gene. Moreover, exons from
genes previously considered to be separate may be spliced
together to generate novel transcripts (9). How to classify
these fusion transcripts is a significant challenge. In addition,
alternative transcription start sites that generate novel 50
untranslated regions continue to be discovered, even for
well-characterized genes (134). Although many of these
novel transcripts are rare and their functional importance is
not understood, our definition of a gene must encompass
the observed diversity of the genome.
This suggests that these genes are unlikely to be candidates for
the dosage-sensitive genes underlying DS phenotypes in the
tissues investigated.
Trisomy of Hsa21 is associated with a small number of
conserved features, occurring in all individuals, including
mild-to-moderate learning disability, craniofacial abnormalities
and hypotonia in early infancy (17). Although these phenotypes
are always found in people with DS, the degree to which an
individual is affected varies. Additionally, trisomy of Hsa21
is also associated with variant phenotypes that only affect
some people with DS, including atrioventricular septal defects
(AVSDs) in the heart, acute megakaryoblastic leukaemia
(AMKL) and a decrease in the incidence of some solid
tumours. This phenotypic variation is likely to be caused by a
combination of environmental and genetic causes. Genetic
polymorphisms in both Hsa21 and non-Hsa21 genes may
account for much of this variation. Genome-wide association
studies to identify these polymorphisms constitute a promising
strategy to gain novel insights into the pathology of DS.
A central goal of DS research is to understand which of the
genes on Hsa21, when present in three copies, lead to each of
the different DS-associated phenotypes, and to elucidate how
increased expression leads to the molecular, cellular and
physiological changes underlying DS pathology. Two distinct
approaches are being taken to address these issues. First,
genomic association studies, such as that recently published
by Lyle et al (18)., may point to genes that play an important
role in pathology. Secondly, a number of animal models of
Hsa21 trisomy have been generated. Recent advances in
chromosome engineering have led to the establishment of
mice trisomic for different sets of mouse genes syntenic to
Hsa21, and a mouse strain, Tc(Hsa21)1TybEmcf (Tc1),
carrying most of Hsa21, as a freely segregating chromosome
(Fig. 1) (19–27). These strains are being used both to map
dosage-sensitive genes on Hsa21 and to understand patho-
logical mechanisms. Here, we review recent advances in the
understanding of DS-associated phenotypes and the develop-
ment of therapeutic strategies to treat them.
RECENT ADVANCES IN UNDERSTANDING
PHENOTYPES ASSOCIATED WITH DS
Development
Trisomy of Hsa21 has a significant impact on the development
of many tissues, most notably the heart and the brain. A recent
paper has suggested that trisomy of the Hsa21 genes, dual-
specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A
(DYRK1A) and regulator of calcineurin 1 (RCAN1), may
have an impact on the development of multiple tissues (28).
DYRK1A is a priming kinase that facilitates the further phos-
phorylation of numerous proteins by other kinases (Fig. 2)
(29–38). It is up-regulated in a number of tissues from
people with DS (39,40). RCAN1 is a regulator of the protein
phosphatase calcineurin (41). Crabtree and colleagues hypoth-
esized that trisomy of these two genes may act synergistically
to alter signalling via the NFAT family of transcription factors
(28). In an independent study, increased DYRK1A gene dosage
was shown to decrease the expression level of RE1-silencing
transcription factor (REST) (42). As REST is required both to
maintain pluripotency and to facilitate neuronal differentiation,
a perturbation in REST expression may alter the
development of many cell types. Indeed, over-expression of
DYRK1A in some animal models is associated with a
number of phenotypes, including heart defects and abnormal
learning and memory (28,33,43–45). However, not all animal
models that over-express DYRK1A exhibit these defects,
suggesting that polymorphisms or differences in the expression
of other genes influence the outcome of DYRK1A trisomy (24).
Trisomy of Hsa21 is associated with a reduction in brain
volume, the size of the hippocampus and cerebellum being
particularly affected (46–49). A similar phenotype is also
observed in the Ts65Dn model (50). Recent studies have
started to elucidate the developmental mechanisms underlying
these important phenotypes. Trisomic granule cell precursors
from the cerebellum have a reduced mitogenic response to
the morphogen sonic hedgehog (51). This was shown to
underlie the reduced number of cerebellar granular cells
observed in the Ts65Dn mouse model of DS. Hypocellularity
in the hippocampus also has a developmental origin (52,53).
Abnormalities in cell-cycle length, apoptosis and neocortical
neurogenesis have been shown to contribute to this phenotype
(53–55). The reduced level of neurogenesis in Ts65Dn adult
hippocampus can be ameliorated by treatment with the anti-
depressant fluoxetine, which is a serotonin reuptake inhibitor
(56). Fluoxetine may promote neurogenesis via a number of
potential mechanisms, including a direct effect on serotonin
levels or via an indirect effect on behaviour. Whether this
drug has similar effect during embryonic development has
yet to be determined.
Ts65Dn pups exhibit a delay in attaining several develop-
mental milestones, such as forelimb grip and the righting
reflex, mimicking the developmental delay observed in
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babies with DS (57). A recent report has demonstrated that
treatment of Ts65Dn embryos with two neuroprotective pep-
tides reduced the delay in achieving a number of sensory
and motor developmental milestones during early post-natal
development (58).
People with DS exhibit craniofacial dysmorphology, includ-
ing a mandible of reduced size. This phenotype is also
observed in the Ts65Dn and Tc1 models (26,59). In the
Ts65Dn model, craniofacial dysmorphology is present from
early post-natal development and may be related to specific
changes in bone development (60,61). The small mandible
in people with DS may be caused by migration and prolifer-
ation defects in mandible precursor (neural crest) cells in the
developing embryo, related to an altered response to sonic
hedgehog (62).
Learning and memory
All people with DS have a mild-to-moderate learning disabil-
ity. Over-expression of a number of Hsa21 genes, including
DYRK1A, synaptojanin 1 and single-minded homologue 2
(SIM2), results in learning and memory defects in mouse
models, suggesting that trisomy of these genes may contribute
to learning disability in people with DS (43,45,63,64). In
addition, trisomy of neuronal channel proteins, such as G-
protein-coupled inward-rectifying potassium channel subunit
2 (GIRK2), may also influence learning in people with DS
(65–67). Recent work has demonstrated that trisomy of a
segment of mouse chromosome 16 (Mmu16) containing 33
genes including DYRK1A, GIRK2 and SIM2 was necessary,
but not sufficient for the hippocampal-based learning deficits
in the Ts65Dn mouse model (68). These data indicate that
trisomy of multiple Hsa21 genes is required for the deficits
in learning associated with DS. Moreover, Hsa21 trisomy
may independently impact on multiple learning pathways.
Recent work on the Tc1 transchromosomic mouse model of
DS has examined in detail the learning pathways affected by
trisomy of Hsa21 (26,69). The Tc1 transchromosomic model
exhibits abnormalities in short-term but not in long-term
hippocampal-dependent learning. The learning deficits are
correlated with specific abnormalities in long-term poten-
tiation (LTP) in the dentate gyrus of the hippocampus. LTP
is an electrophysiological process proposed to be the cellular
Figure 1. Mouse models of Hsa21 trisomy and monosomy. Hsa21 (orange) is syntenic with regions of mouse chromosomes 16 (Mmu16, blue), 17 (Mmu 17,
green) and 10 (Mmu10, grey). The Tc1 mouse model carries a freely segregating copy of Hsa21, which has two deleted regions, such that the model is trisomic
for the majority of genes on Hsa21. The Dp1Yu, Ts65Dn, Ts1Cje and Ts1Rhr mouse models contain an additional copy of regions of mouse chromosome 16 that
are syntenic with Hsa21, such that they are trisomic for a proportion of Hsa21 genes. The Ms1Rhr mouse model contains a deletion of a region of Mmu16; the
Ms1Yah mouse model contains a deletion of a region of Mmu10. Hence, these models are monosomic for the genes in these deleted Hsa21 syntenic segments.
Figure 2. Phosphorylation targets of DYRK1A. The Hsa21-encoded kinase
DYRK1A has been shown to phosphorylate a multitude of targets, which
have been implicated in a number of biological processes and DS-associated
phenotypes, including endocytosis and AD.
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basis of learning and memory (70). These data provide insight
into which learning mechanisms may be affected by Hsa21
trisomy and can be used to further understand their genetic
cause. Structural abnormalities may contribute to these deficits
in learning and memory. Indeed, a correlation between
specific synaptic abnormalities in the hippocampus of the
Ts(16C-tel)1Cje (Ts1Cje) mouse and a defect in LTP has
been reported (71). Moreover, a recent paper has demonstrated
an alteration in the amounts of a number of synaptic com-
ponents in the hippocampus of the Ts65Dn mouse (72).
Alzheimer’s disease
People with DS have a greatly increased risk of early-onset
Alzheimer’s disease (AD). By the age of 60, between 50
and 70% of the people with DS develop dementia (73–77).
The known AD risk factor amyloid precursor protein (APP)
is encoded on Hsa21. Trisomy of APP is likely to make a sig-
nificant contribution to the increased frequency of dementia in
people with DS. Indeed, triplication of a short segment of
Hsa21 that includes APP in people without DS has been
recently shown to be associated with early-onset AD. A
number of features of neurodegeneration have been observed
in mouse models of DS (78–86). Loss of basal forebrain
cholinergic neurons (BFCNs) occurs early in AD and also is
observed in the Ts65Dn mouse model (87). Degeneration of
BFCNs in Ts65Dn mice is dependent on trisomy of APP
and is mediated by the effect of increased APP expression
of retrograde axonal transport (83).
Hsa21 genes other than APP may also contribute to the early
onset of AD in people with DS (33,34,40,88–97). Indeed, the
Ts1Cje mouse model, which is not trisomic for APP, exhibits
tau hyperphosphorylation, an early sign of AD (98). Recent evi-
dence suggests that trisomy of DYRK1A may contribute to the
development of AD in people with DS. DYRK1A can phos-
phorylate Tau at a key priming site that permits its hyperpho-
sphorylation (33,36,40,95). DYRK1A may also influence the
alternative splicing of Tau and the phosphorylation of APP
(34,99). A reduction in the level of protein phosphatase 2A
and a decrease in the activity of a-secretase in the brains of
people with DS have also been reported, both of which may
contribute to AD in this population (94,100). Further studies
are required to determine the identity of the trisomic genes
that contribute to these phenotypes.
Heart defects
Trisomy of Hsa21 is associated with a number of congenital
heart defects, the most common being AVSD that occurs in
20% of the people with DS (101). Mutations in the
non-Hsa21 CRELD1 gene may contribute to the development
of AVSD in DS (102). CRELD1 has also been linked to
AVSDs by mapping the deletion breakpoints, on chromosome
3, in people with 3p-syndrome. Further studies are required to
determine the identity of other genes that are important for
heart development in people with DS. A number of Hsa21
trisomy mouse models exhibit heart defects similar to those
observed in DS, suggesting that trisomy of one or more of
the approximately 100 genes common to these models influ-
ences development of the heart (22,26,103,104).
Leukaemia and cancer
DS increases the risk of developing AMKL and acute lympho-
blastic leukaemia (ALL). Approximately 10% of the DS new-
borns present with a transient myeloproliferative disorder
(TMD), characterized by a clonal population of megakaryoblasts
in the blood. This transient disease usually spontaneously
resolves; however, 10–20% of the DS patients with TMD
develop AMKL before 4 years of age (reviewed in 105). The
development of TMD requires both trisomy 21 and mutations
in the transcription factor GATA1 (106,107). It is likely that
further mutations are required for TMD to develop into AMKL.
The GATA1 mutations found in TMD and AMKL always have
the same effect, causing translation to initiate at the second
ATG of the coding region, leading to the production of a
shorter protein, termed GATA1s. Trisomy of Hsa21 on its own,
even in the absence of GATA1s, leads to an expansion of the
megakaryocyte-erythroid progenitor population in fetal livers
from human DS abortuses (108,109). These data suggest
that trisomy of Hsa21 perturbs hematopoiesis, making
megakaryocyte-erythroid progenitors susceptible to the effects
of GATA1s, thereby promoting development of TMD. Several
groups have reported the presence of mutations in Janus Kinase
3 (JAK3) in a small proportion of TMD/AMKL patients
(110–115). It was suggested that JAK3 inhibitors could be used
as a therapy (111,114). However, both loss- and gain-of-function
mutations have been found, so this may not be a viable treatment.
Stem cell factor/KIT signalling has recently been demonstrated
to stimulate TMD blast cell proliferation, and inhibitors of
this pathway may be a treatment for severe TMD (116).
Attempts have been made to model these disorders in mice
with a view to establishing which genes on Hsa21 need to be
present in three copies in order to induce disease. A study of
the Ts65Dn mouse model showed that it developed a
late-onset myeloproliferative disorder, but did not develop
leukaemia (117). It may be that the Ts65Dn model is not
trisomic for the relevant dosage-sensitive genes required for
the development of AMKL or that the expression of a
mutant form of GATA1 will be required to increase the
frequency of leukaemogenesis in this mouse model of DS.
The genetic events involved in DS-ALL are less well
understood than those in DS-AMKL. A number of studies have
reported DS-ALL cases with chromosomal abnormalities,
gain-of-function mutations in JAK2 and submicroscopic del-
etions of genes including ETV6,CDKN2A andPAX5 (118–121).
Although the incidence of leukaemia and cancer of the testis
are increased in DS, the risk of developing most solid tumours
is reduced (122,123). Crossing mouse models of DS with mice
heterozygous for the Apcmin mutation reduced the number
of tumours, which would normally accumulate in this model
of colon cancer (124). Protection against the development of
tumours required three copies of the Hsa21 ‘proto-oncogene’
Ets2, suggesting that in this context, Ets2 may be acting as a
tumour suppressor (124).
Hypertension
People with DS have been reported to have a reduced inci-
dence of hypertension (125,126). Trisomy of the Hsa21 micro-
RNA hsa-miR-155 may contribute to this (12). Hsa-miR-155
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is proposed to specifically target one allele of the type-1
angiotensin II receptor (AGTR1) gene, resulting in its under-
expression, which may contribute to a reduced risk of hyper-
tension. Further studies are required to validate this hypothesis
and determine whether other genes may also protect people
with DS against hypertension.
RECENT ADVANCES IN THERAPY AND FUTURE
PROSPECTS
Recent interest in therapy for people with DS has focused on
pharmacological treatment to enhance cognition. A number of
compounds have been shown to improve learning in the
Ts65Dn mouse model. Chronic treatment with picrotoxin
or pentylenetetrazole improved hippocampal-based learning
and LTP deficits in Ts65Dn mice, even after treatment had
ceased (127). These compounds reduce gamma-aminobutyric
acid-mediated inhibition in the hippocampus and are proposed
to improve cognition by releasing normal learning from excess
inhibition. Learning in Ts65Dn mice is also improved by
the non-competitive N-methyl-D-aspartic acid receptor
(NMDAR) antagonist, memantine (128). Memantine partially
inhibits the opening of the NMDAR and is proposed to counter
the effect of trisomy of RCAN1 on the function of the receptor.
Further studies and clinical trials are required to further
investigate the potential of these drugs to improve cognition
in people who have DS.
To develop new therapeutic targets, it is necessary to deter-
mine the identity of genes that contribute to DS phenotypes.
This requires a precise and standardized definition of
phenotype. Ideally, these measurements should be formulated
into a standardized protocol that can be applied at multiple
centres, to permit sufficiently large numbers of samples for
meaningful analysis to be collected. This can be facilitated
by a carefully designed and curated biobank of detailed pheno-
typic data alongside DNA and tissue samples from participat-
ing individuals. These collections can then be used for both
candidate gene and genome-wide analyses, by different inves-
tigators, permitting the identification of both dosage-sensitive
trisomic Hsa21 and non-Hsa21 genes that contribute to DS
phenotypes. Pooling of large data sets has led to recent import-
ant findings in the study of schizophrenia, diabetes and
obesity, illustrating the importance of large-scale collaboration
(129–132). The careful collection of additional patient data
will add much to our current understanding of DS.
As recent progress demonstrates, mouse models can be used
in parallel with data collected from people with DS to test
genetic associations, to explore biological mechanisms and
to trial therapies. In addition to the long-standing Ts65Dn
and Ts1Cje models, the newly developed mouse strains such
as Tc1, Dp1Yu and Ts1Rhr have generated a range of
models with distinct sets of trisomic genes (Fig. 1) (19–27).
Furthermore, the crossing of these strains with mice-bearing
deletions of chromosomal segments syntenic to Hsa21, such
as Ms1Yah and Ms1Rhr (Fig. 1), will allow systematic
mapping and eventually identification of the dosage-sensitive
genes causing DS-associated pathology.
DS was once thought to be an intractable condition because
of the genetic complexity underlying it. Here, we have
described recently reported breakthroughs in the understand-
ing of Hsa21 trisomy, illustrating that research efforts in this
field are making significant strides to understand and to
develop treatments for the debilitating aspects of the syn-
drome. Many issues vital to the health and well-being of
people with DS remain to be studied, making this an important
and exciting time for Hsa21 trisomy research.
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